|
|
 |
|
Viewing report
|
|
|
|
China Anti-Diabetic Drug Market Report 2009
Draco Healthcare Consulting LLC, Jan 2009, Pages: 97
Diabetes Mellitus (DM) is a chronic disease that occurs when the pancreas does not produce enough insulin, or alternatively, when the body cannot effectively use the insulin it produces. When China started its economic reform in 1978, the diabetes disease rate was about 0.6% in the Chinese population. As China entered the rapid growth phase of its economic development, the diabetes disease rate has arisen rapidly. In 1995, the diabetes disease rate reached 1.5% and in 2000 the diabetic disease rate was 2.4% with the total number of diabetes patients at 31 million in China. The average addition of new diabetes patients each year was about 1.5 millions.
Due to the increased numbers of diabetes patients and the improvements of living standards, the market size of diabetes drugs has increased steadily in China. The market size of diabetes drugs in 2002 was about RMB 4.187 billion and increased to RMB 7.495 billion in 2007 (USD 1.071 billion at 7:1 USD:RMB exchange rate) with an average annual growth of 13%. The annual growth rate from 2006 to 2007 was a significant 20.98%. This report has systemically analyzed the Chinese diabetes drug market. All drug data are based on hospital drug prescription and drug purchasing data from the hospital data monitor system that the China Nan Fang Institute of Medical and Economic Information has developed and maintained (Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA).
Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou, covering significant percentages of all hospitals in these regions. Market shares from all major players including multinational and Chinese pharmaceutical companies and their major diabetes products are analyzed systemically based on data from significant number of Chinese hospitals. The comprehensive hospital utilization data of major diabetes drugs will present you a clear picture of the competition landscape of Chinese diabetes drug market and the market potential for your company’s product(s) that already marketed in China or if you are planning to bring your drugs to the China market.
This China Diabetes Drug Market Report has been a Must-have reference for all levels of decision makers in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique drug prescription and utilization data can provide valuable information for new product development, marketing and strategic planning functions for pharmaceutical companies. Compared to expensive customized drug reports in China, this multi-client report provides significant savings and great cost/benefit to pharmaceutical companies and interested parties.
Product Mentioned:
- Insulin
- Acarbose
- Metformin
- Repaglinide
- Rosiglitazone
- Gliclazide
- Glimepiride
- Gliquidone
- Glipizide
- Pioglitazone
Customers who bought this item also bought
Market Research of Diabetes and its Treatment Medicine-Insulin in China, 2008
The Diabetes Market Outlook: Market Analysis of Future Growth and Leading Players by Sector
BRIC Diabetes Drugs Market
China Dermatosis Drug Market Report 2009
China Anti-Cancer Drug Market Report 2009
China Senile Dementia Drug Market Report 2009
China Asthma Drug Market Report 2009
The World Diabetes Market, 2007-2025: An analysis of Diabetes Drug and Insulin Market
Diabetes Market Forecast to 2015
The Diabetes Market Outlook To 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
Diabetes, Metabolic Syndrome and Cardiovascular Disease
Insulin Delivery Systems - Global Strategic Business Report
|
|
|
|
